Results 101 to 110 of about 10,641 (185)

Le sevrage tabagique: une nouvelle molécule orale, la varenicline (Champix).

, 2007
Varenicline orally administered nicotine acetylcholine receptor partial agonist is approved by the US FDA and the MEA for use as an aid to smoking cessation therapy.
Perez Bogerd, Silvia, Sternon, Jacques
core  

Rotavapour-Assisted Varenicline–Maltodextrin Amorphous Solid Dispersion for Mitigation of N-Nitroso-Varenicline

N-Nitroso-varenicline (NNV) is a nitrosamine drug substance-related impurity (NDSRI) of regulatory concern in varenicline tartrate, a widely prescribed smoking-cessation therapy.
Santosh Bhende, Pravin Chaudhari, Atul Phatak   +2 more
core   +1 more source

Genome-wide association study of varenicline-aided smoking cessation

Introduction Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist with the highest therapeutic efficacy of any pharmacological smoking cessation aid and a 12-month cessation rate of 26%.
Sundararajan Srinivasan (11467215), Chiara Batini (3259911), Martin D Tobin (7795649), Estonian Biobank Research Team (13109565), David J Shepherd (8950499), Khaled F Bedair (20557226), Erik Abner (18839689), Robert C Free (8880545), Richard Packer (7522310), Sara Paciga (20557229), Qingning Wang (8950478), Craig Hyde (7829471), Nicola F Reeve (8880548), Colin Palmer (165015), Tõnu Esko (102379), Ewan Pearson (2830736), Kadri Reis (17127685), Anders Malarstig (108961), Kayesha Coley (20335695), Catherine John (7757003)   +19 more
core   +2 more sources

Vaping cessation interventions: A narrative review of randomized controlled trials. [PDF]

Tob Prev Cessat
Zolotarova T, Moiz A, Lelièvre A, Eisenberg MJ.   +3 more
europepmc   +1 more source

Neuropharmacology of Nicotine Addiction and Therapeutic Strategies for Smoking Cessation. [PDF]

Biology (Basel)
Hefny AA, Karuturi RC, Kalyaanamoorthy S, Rao PPN, Ganesan A.   +4 more
europepmc   +1 more source

The effectiveness and value of cytisinicline for smoking cessation: A summary from the institute for clinical and economic review's midwest comparative effectiveness public advisory council. [PDF]

J Manag Care Spec Pharm
Nikitin D, Tice JA, Suh K, Sanchez S, Richardson M, Phillips M, Carlson JJ, Chan HH, Rind DM, Agboola F.   +9 more
europepmc   +1 more source

App-based contingency management to reduce heavy drinking days among smokers receiving varenicline: Feasibility, acceptability, and efficacy indicators from a phase I analog trial. [PDF]

Exp Clin Psychopharmacol
Miguel AQC, Akana N, Ryan R, Schmidt A, Hovland S, Stark B, Colletto S, Bowen A, Rodin N, Smith CL, McPherson SM.   +10 more
europepmc   +1 more source

Discriminative stimulus and locomotor activity profiles of nicotine and varenicline. [PDF]

Pharmacol Biochem Behav
Kusi-Boadum NK, Taylor CM, Shetty RA, Sumien N, Forster MJ.   +4 more
europepmc   +1 more source

Narrative Review of Novel Nicotine-Delivery Systems and Emerging Pharmaceuticals for Tobacco Cessation. [PDF]

Medicines (Basel)
Mutukula S, Gagne-Hatfield T, Dunbar ZR.
europepmc   +1 more source

An Open-Label Trial of Effects of Varenicline in Nonconstipation Irritable Bowel Syndrome and Pain. [PDF]

Clin Gastroenterol Hepatol
Matar A, Busciglio I, Eckert D, Linden DR, Harmsen WS, Camilleri M.   +5 more
europepmc   +1 more source